FLT3 and acute myeloid leukemia: FLT3 point mutation in the tyrosine kinase domain (TKD) is present in 5% of AML patients, and mutations at Asp835 which most commonly occur are considered to be a part of the AML drug resistance mechanism10–13 (Figure 1).